FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2477-2480 December 7, 2006 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kahn, S. E. PubMed Citation

The twin epidemics of obesity and type 2 diabetes mellitus have spawned a public health crisis. In the United States, an estimated 1.5 million new cases of diabetes occur every year,¹ and the projected microvascular and cardiovascular complications² — already the greatest cause of blindness, kidney failure, and amputations in the Western world, and a substantial contributing factor in heart disease — are likely to become the major cause of preventable disease and premature death in this millennium.

The gravity of this epidemic is reflected by evidence-based efforts to stem it.^3,4 Moreover, in the United States, approval of five new . . . [Full Text of this Article]

Source Information

From the Diabetes Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.

This article was published at www.nejm.org on December 4, 2006.

This article has been cited by other articles:

• Scarpello, J. H., Howlett, H. C. (2008). Metformin therapy and clinical uses. Diabetes and Vascular Disease Research 5: 157-167 [Abstract]  
• Hadler, N. M. (2008). Oral Hypoglycemics and Diabetic Nephropathy. CJASN 3: 159-162 [Full Text]  
• Hollander, P., Yu, D., Chou, H. S. (2007). Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes. Arch Intern Med 167: 1284-1290 [Abstract] [Full Text]  
• Psaty, B. M., Furberg, C. D. (2007). Rosiglitazone and Cardiovascular Risk. NEJM 356: 2522-2524 [Full Text]  
• Ceglia, L., Lau, J., Pittas, A. G. (2007). Effect of Inhaled Insulin on Fasting and Postprandial Plasma Glucose. ANN INTERN MED 146: 821-822 [Full Text]  
• Kahn, S. E., Zinman, B. (2007). Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes. Diabetes Care 30: 1672-1676 [Full Text]  
• Bloomgarden, Z. T., Inzucchi, S. E., Irony, I., Parks, M. H., Meyer, R. J., Mintz, M. L., Raz, I., Eldor, R., Nathan, D. M. (2007). New Treatments for Diabetes. NEJM 356: 2219-2223 [Full Text]  
• Hirsch, I. B. (2007). Impressions From the IDF in South Africa. DOC News 4: 9-9 [Full Text]  
• (2006). Metformin remains the logical first line drug for type 2 diabetes. BMJ 333: 1265-1266 [Full Text]  
• (2006). Which Drug for Initial Treatment of Type 2 Diabetes?. JWatch General 2006: 1-1 [Full Text]